Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(3):235-237
DOI: 10.5428/pcar20190320
Pharmaceutical care for a patient with refractory cancer pain treated by intrathecal infusion of hydromorphone
1. SUN Qiuyan(a 390608106@qq.com)
2. HU Jian’e(a 272879496@qq.com)
3. LI Xinyu(a )
Welcome to PCAR! You are the number 38 reader of this article!
Please cite this article as:
SUN Qiuyan,HU Jian’e,LI Xinyu,. Pharmaceutical care for a patient with refractory cancer pain treated by intrathecal infusion of hydromorphone[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(3): 235-237.
References:
1. Haumann J,Joosten E B A,Everdingen M H J V D B.Pain prevalence in cancer patients: status quo or opportunities for improvement?[J].Curr Opin Support Palliat Care, 2017, 11(2):99-104.
2. Vayne-Bossert P,Afsharimani B,Good P,et al.Interventional options for the management of refractory cancer pain-what is the evidence[J].Support Care Cancer, 2016, 24(3):1429-1438.
3. Kim H J,Kim Y S,Park S H.Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study[J].BMC Palliat Care,2015,14(1):41-46.
4. Chinese Rheumatism Data Center,Chinese Systemic Lupus Erythematosus Treatment and Research Group.Recommendation for the prevention and treatment of non-steroidal anti-infalmmatory drug-induced gastrointestinal ulcers and its complications[J].Chin J Intern Med, 2017, 56(1):81-85.In Chinese with English abstract.
5. Daeninck P,Gagnon B,Gallagher R,et al.Canadian recommendations for the management of breakthrough cancer pain[J].Curr Oncol,2016,23(2): 96-108.
6. Lin C P,LIN Wenying,LIN Fengsheng,et al.Efficacy of intrathecal drug delivery system for refractory cancer pain patients:a single tertiary medical center experience[J].J Formos Med Assoc,2012,111(5):253-257.
7. Smith T J,Coyne P J,Staats P S,et al.An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM)[J].Ann Oncol,2005,16(5):825-833.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口